Balyasny Asset Management
KYTX icon

Balyasny Asset Management’s Kyverna Therapeutics KYTX Stock Holding History

Balyasny Asset Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$856K Sell
96,048
-1,029,273
-91% -$9.14M ﹤0.01% 2296
2026
Q1 		$9.71M Buy
1,125,321
+144,452
+15% +$1.2M 0.01% 1042
2025
Q4 		$9.22M Buy
+980,869
New +$7.28M 0.01% 1066
2024
Q4 		– Sell
-33,308
Closed -$163K – 3350
2024
Q3 		$163K Buy
+33,308
New +$257K ﹤0.01% 2597
2024
Q2 		– Sell
-16,721
Closed -$415K – 3199
2024
Q1 		$415K Buy
+16,721
New +$467K ﹤0.01% 2122

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Balyasny Asset Management's KYTX Position: Q2 2026 in Review

Balyasny Asset Management reduced its Kyverna Therapeutics (KYTX) stake by 91% in Q2 2026, selling an estimated $9.14M and leaving 96,048 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

Balyasny Asset Management first reported a position in KYTX in Q1 2024 and has held it in 5 quarters since. The position peaked at $9.71M in Q1 2026. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Balyasny Asset Management held 96,048 shares of Kyverna Therapeutics worth $856K as of Q2 2026.
  • Balyasny Asset Management sold 1,029,273 Kyverna Therapeutics shares in Q2 2026, an estimated $9.14M.
  • Kyverna Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2296 holding.
  • Balyasny Asset Management first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Balyasny Asset Management's Kyverna Therapeutics position peaked at $9.71M in Q1 2026.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.